Literature DB >> 27300190

[Botulinum toxin type A in headache treatment : Established and experimental indications].

C Gaul1, D Holle-Lee2, A Straube3.   

Abstract

In recent years botulinum toxin type A has been used increasingly more in the treatment of specific headache disorders. Especially regarding chronic migraine with and without combined medication overuse, convincing randomized studies have proven the efficacy of this treatment option and have led to approval for this indication. Regarding other headache entities, such as episodic migraine, tension-type headache, trigeminal autonomic cephalalgia (TAC), neuralgic, neuropathic and myofascial pain, currently available scientific data on the efficacy of botulinum toxin type A are scarce and often ambiguous. The exact underlying mechanisms of the influence of botulinum toxin type A on the pathophysiology of headache are not completely clear but an influence on the release of calcitonin gene-related peptide (CGRP) seems to play a crucial role. This article summarizes the most important studies as well as experiences of treatment with botulinum toxin type A regarding different headache entities.

Entities:  

Keywords:  Medication overuse; Migraine; Tension type headache; Trigeminal autonomic cephalalgia; Trigeminal neuralgia

Mesh:

Substances:

Year:  2016        PMID: 27300190     DOI: 10.1007/s00115-016-0138-5

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  46 in total

1.  Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis.

Authors:  Parisa Gazerani; Sammy Au; Xudong Dong; Ujendra Kumar; Lars Arendt-Nielsen; Brian E Cairns
Journal:  Pain       Date:  2010-08-21       Impact factor: 6.961

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  Botulinum toxin type A's efficacy in nummular headache.

Authors:  Petcharat Dusitanond; William Young
Journal:  Headache       Date:  2008-10       Impact factor: 5.887

Review 4.  Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence.

Authors:  M Linde; K Hagen; L J Stovner
Journal:  Acta Neurol Scand Suppl       Date:  2011

5.  OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

Authors:  Stephen D Silberstein; Andrew M Blumenfeld; Roger K Cady; Ira M Turner; Richard B Lipton; Hans-Christoph Diener; Sheena K Aurora; Mai Sirimanne; Ronald E DeGryse; Catherine C Turkel; David W Dodick
Journal:  J Neurol Sci       Date:  2013-06-19       Impact factor: 3.181

Review 6.  Central sensitization in tension-type headache--possible pathophysiological mechanisms.

Authors:  L Bendtsen
Journal:  Cephalalgia       Date:  2000-06       Impact factor: 6.292

7.  [Therapy and care of patients with chronic migraine: expert recommendations of the German Migraine and Headache Society/German Society for Neurology as well as the Austrian Headache Society/Swiss Headache Society].

Authors:  A Straube; C Gaul; S Förderreuther; P Kropp; M Marziniak; S Evers; W H Jost; H Göbel; C Lampl; P S Sándor; A R Gantenbein; H-C Diener
Journal:  Nervenarzt       Date:  2012-12       Impact factor: 1.214

Review 8.  Botulinum Toxin for Neuropathic Pain: A Review of the Literature.

Authors:  Hyun-Mi Oh; Myung Eun Chung
Journal:  Toxins (Basel)       Date:  2015-08-14       Impact factor: 4.546

9.  Botulinum toxin type-A therapy in cluster headache: an open study.

Authors:  Petra Sostak; Phillip Krause; Stefanie Förderreuther; Veronika Reinisch; Andreas Straube
Journal:  J Headache Pain       Date:  2007-09-24       Impact factor: 7.277

10.  Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial.

Authors:  Jan Burmeister; Dagny Holle; Eva Bock; Claudia Ose; Hans-Christoph Diener; Mark Obermann
Journal:  Trials       Date:  2015-12-03       Impact factor: 2.279

View more
  3 in total

Review 1.  Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Authors:  Till Sprenger; M Viana; C Tassorelli
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 2.  Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Authors:  Claus M Escher; Lejla Paracka; Dirk Dressler; Katja Kollewe
Journal:  Ther Adv Neurol Disord       Date:  2016-11-16       Impact factor: 6.570

Review 3.  Botulinum Toxin-A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches.

Authors:  Katarzyna Kępczyńska; Izabela Domitrz
Journal:  Toxins (Basel)       Date:  2022-09-05       Impact factor: 5.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.